Applied DNA Schedules Fiscal 2021 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 13, 2021

Applied DNA Schedules Fiscal 2021 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 13, 2021




Applied DNA Schedules Fiscal 2021 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 13, 2021

STONY BROOK, N.Y.–(BUSINESS WIRE)–$APDN #COVID19Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it will report fiscal 2021 second quarter financial results after market close on Thursday, May 13, 2021. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘IR Calendar’ section of the Company’s corporate website and embedded into the live webcast.

Conference Call and Webcast Information – Live

Date:

 

Thursday, May 13, 2021, at 4:30 p.m. Eastern Daylight Time

Dial in:

 

844-887-9402

 

 

412-317-6798 (international)

Hosts:

 

Dr. James A. Hayward, chairman, president, and CEO

 

 

Beth Jantzen, chief financial officer

Webcast:

 

https://services.choruscall.com/mediaframe/webcast.html?webcastid=YaMBr3pT

Conference Call and Webcast Information – Replay

A telephonic replay of the conference call will be available for one week beginning one hour after the end of the live conference call.

Dial in:

 

877-344-7529

 

 

412-317-0088 (international)

 

 

Access Code: 10154121

Webcast:

 

https://services.choruscall.com/mediaframe/webcast.html?webcastid=YaMBr3pT

Availability:

 

Telephonic replay: until Thursday, May 20, 2021; webcast replay: 1 year

The webcast and accompanying PowerPoint presentation will also be archived on the ‘IR Calendar’ page listed under the Investor Relations drop-down menu on the Company’s website.

About Applied DNA Sciences

Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction (“PCR”)-based manufacturing platform that allows for the large-scale production of specific DNA sequences.

The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. Applied DNA has also established a COVID-19 diagnostic and testing offering that is in the early stages of commercialization and is grounded in the Company’s deep expertise in DNA.

The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include Gov/Mil, textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under ticker symbol ‘APDN,’ and its publicly traded warrants are listed on OTC under ticker symbol ‘APPDW.’

Applied DNA is a member of the Russell Microcap® Index.

Contacts

Investor contact: Sanjay M. Hurry, Applied DNA Sciences, 917-733-5573, sanjay.hurry@adnas.com
Web: www.adnas.com
Twitter: @APDN